ASH 2023 | UM171 improves outcomes of cord-blood transplants in high-risk leukemia
Filippo Milano, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, outlines a study investigating UM171-expanded cord blood transplants (CBT) in patients with high and very high-risk leukemias. UM171 is a small molecule that expands hematopoietic stem and progenitor cell lines and, when administered with CBT, produces extremely promising results in this cohort, with the majority of patients exhibiting a prolonged disease-free period. Following this success, a randomized trial is being planned to assess this treatment in larger cohorts. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: ExCellThera Inc.
